Global Health Limited reports record Q1 FY27 Total Income as EBITDA grows 23.9%

Global Health Limited reports record Q1 FY27 Total Income as EBITDA grows 23.9%​

Gurugram, July 30, 2026: Global Health Limited, a major private multi-specialty tertiary care provider operating in the North and East regions of India, has announced its unaudited consolidated financial results for the quarter ending June 30, 2026. The company reported a record quarterly Total Income of INR 13,262 million, marking a 26.2% increase year-over-year (y-o-y).

The Q1 FY27 performance showed robust growth across key operational and financial metrics. EBITDA for the consolidated entity stood at INR 3,153 million, reflecting a 23.5% y-o-y growth and achieving margins of 23.8%. This contrasts with an EBITDA (ex-Noida) of INR 3,201 million, which grew by 23.9% y-o-y with improved margins of 25.8%.

Financial Results Overview: Q1 FY2027​

The unaudited consolidated financial results provide a clear picture of the company's performance against previous quarters and the current fiscal year comparison. Key figures are detailed below:


Note: The provided data includes consolidated figures for both reported EBITDA and specific segment performance details regarding Noida.

Operational Highlights and Strategic Expansion​

The company noted sustained volume growth, with the in-patient count increasing by 27.7% and the out-patient count rising by 34.5% y-o-y. Occupied bed days increased by 21.1% y-o-y, resulting in an occupancy rate of approximately 63%, which stood at 66% when excluding the Noida unit.

ARPOB (Average Revenue Per Occupied Bed) reached INR 70,244, up 5.5% y-o-y. This improvement was attributed to changes in case mix and reduced Average Length of Stay (ALOS), which decreased from 3.03 days in Q1 FY26 to 2.87 days in Q1 FY27.

Strategic developments included adding a total of 72 new beds across the network during the quarter: 51 beds were added at Noida and 21 beds were added at Lucknow. The company also onboarded over 70 doctors, including more than 50 senior clinicians across its Medanta network.

Business Segment Performance​

The performance of the specific units showed variation in the quarter. While Patna and Lucknow continued to show consistent y-o-y growth, the Noida unit saw a decline in EBITDA losses compared to Q4 FY26. The hospital in Noida recorded Total Income of INR 855 million and an EBITDA loss of INR 49 million in Q1 FY27, compared to INR 525 million in total income and an EBITDA loss of INR 236 million reported in Q4 FY26.

In addition to core services, the OPD Pharmacy business demonstrated strong growth, with revenue increasing by 50.9% y-o-y to INR 609 million. International Patients Revenue also increased by 23.0% y-o-y to INR 782 million.

Future Projects and Commitments​

Mr. Pankaj Sahni, Group CEO and Director, commented on the Q1 FY2027 results, stating that the quarter marked a strong beginning for FY27, driven by significant patient volume growth and improved realizations. He noted that the Noida unit has begun contributing meaningfully in a quarterly basis, alongside consistent growth witnessed in Patna and Lucknow.

Looking ahead, Global Health Limited plans to operationalize an 80-bed cancer facility in Indore within the next few months. On the projects front, the company scaled up its plan for Guwahati, which will feature a 650-bedded super specialty hospital with a total capex of INR 9,700 million. Furthermore, the company is committed to expanding its network and expects to add 2,950 beds across five greenfield projects over the coming years.

A detailed financial breakdown for Q1 FY2027 highlights are as follows:

MEDANTA Stock Price Movement​

Shares of Global Health Limited today slipped by 0.69% to settle at ₹1416.4, shedding ₹9.90 in trading. The stock saw a total volume of 234,633 shares traded during the post-market session.